Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00473083 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT00473083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00473083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
August 31, 2013
Enrollment
150 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

rash